ClinicalTrials.gov
public full text
Public Domain
A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B
UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators determine the optimal recommended dosage of HTS to provide a basis for Phase III confirmatory clinical research.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed#843200
- Simvastatin for the Treatment of Chronic Hepatitis B#907016
- Treatment outcome of tenofovir disoproxil fumarate (TDF) among chronic hepatitis B patients: A retrospective review in Hospital Sultanah Nur Zahirah (HSNZ)#190819
- Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection#852298
- EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection#880810
Record · ID 892820
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive